Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASN-002 with or without 5-FU for nodular basal cell carcinoma
ACTRN12615001017516Phase 2Completed
- Sponsor
- Ascend Biopharmaceuticals Ltd.
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gusacitinib and fluorouracil in basal cell carcinoma (BCC) and Basal cell nevus syndrome (BCNS) (5 cohorts), sponsored by Ascend Biopharmaceuticals Ltd. Primary endpoint: Safety of ASN-002 alone or in combination with 5-FU. Started Sep 2015; status: completed.
02
Drugs
gusacitinibfluorouracil
03
Conditions
basal cell carcinoma (BCC)Basal cell nevus syndrome (BCNS)
Beyond the preview
Go deeper on ACTRN12615001017516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615001017516.